HomeCompareBDVC vs PFE

BDVC vs PFE: Dividend Comparison 2026

BDVC yields 57.14% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDVC wins by $213.8K in total portfolio value
10 years
BDVC
BDVC
● Live price
57.14%
Share price
$3.50
Annual div
$2.00
5Y div CAGR
-5.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$264.9K
Annual income
$36,168.16
Full BDVC calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — BDVC vs PFE

📍 BDVC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDVCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDVC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDVC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDVC
Annual income on $10K today (after 15% tax)
$4,857.14/yr
After 10yr DRIP, annual income (after tax)
$30,742.94/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, BDVC beats the other by $7,613.98/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDVC + PFE for your $10,000?

BDVC: 50%PFE: 50%
100% PFE50/50100% BDVC
Portfolio after 10yr
$158.0K
Annual income
$31,689.35/yr
Blended yield
20.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

BDVC
No analyst data
Altman Z
0.4
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDVC buys
0
PFE buys
0
No recent congressional trades found for BDVC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDVCPFE
Forward yield57.14%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-5.9%13.2%
Portfolio after 10y$264.9K$51.1K
Annual income after 10y$36,168.16$27,210.54
Total dividends collected$196.9K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BDVC vs PFE ($10,000, DRIP)

YearBDVC PortfolioBDVC Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$16,077$5,377.14$9,161$701.38+$6.9KBDVC
2$24,805$7,602.67$8,610$859.79+$16.2KBDVC
3$36,857$10,315.88$8,366$1,081.25+$28.5KBDVC
4$52,918$13,480.14$8,483$1,405.66+$44.4KBDVC
5$73,642$17,020.62$9,084$1,907.24+$64.6KBDVC
6$99,628$20,830.96$10,418$2,732.78+$89.2KBDVC
7$131,386$24,783.91$13,007$4,193.56+$118.4KBDVC
8$169,327$28,743.69$18,010$7,005.87+$151.3KBDVC
9$213,758$32,578.02$28,216$12,979.89+$185.5KBDVC
10$264,889$36,168.16$51,081$27,210.54+$213.8KBDVC

BDVC vs PFE: Complete Analysis 2026

BDVCStock

Franklin BSP Lending Corporation is a business development company specializing in investing in middle market companies, leverage buyouts, acquisitions, recapitalizations, growth opportunities, venture debt, CLO equity, delayed draw term loans, rescue financing, distressed or turnaround situations, and bridge loans and financing. It invests in the debt and equity of private held companies. It typically prefers to invest in unitranche, senior secured debt, senior unsecured debt, second lien secured debt, equity co-investments, subordinated secured debt, subordinated unsecured debt, mezzanine debt, convertible debt, convertible preferred equity, preferred equity, common equity, warrants. It seeks to invest in business services, energy, general industrial, government, healthcare, software, specialty finance; restaurants, TMT, food and beverage, and consumer products. It prefers to take majority stakes in investments. It invests throughout the United States and Canada. It invests between $1 million and $25 million in established companies with revenues between $5 million and $1000 million and stable operating cash flows. Within middle market loans, the investment size across the BSP private debt platform typically ranges from $25 million to over $250 million in companies with EBITDA between $10 million and $100 million. It seeks to have Board representation or Board Observation rights in its portfolio companies.

Full BDVC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this BDVC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDVC vs SCHDBDVC vs JEPIBDVC vs OBDVC vs KOBDVC vs MAINBDVC vs JNJBDVC vs MRKBDVC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.